Table 1. Clinical and pathologic characteristics (n = 1457).
| Age, yr, mean (SD) | 66.7 (6.5) | |
| PSA, ng/ml, median (IQR) | 6.53 (5.10-8.72) | |
| Gleason score, n (%) | ||
| ≤ 6 | 1218 (83.6) | |
| 7 | 239 (16.4) | |
| Clinical stage, n (%) | ||
| T1c | 1102 (75.6) | |
| T2a | 267 (18.4) | |
| T2b | 56 (3.8) | |
| Tx | 32 (2.2) | |
| Risk group, n (%) | ||
| Low | 991 (68.0) | |
| Intermediate | 441 (30.3) | |
| NA | 25 (1.7) | |
| PPC, median (IQR) | 25 (14.3-40.0) | |
| Prostate volume at treatment, ml, mean (SD) | 38.1 (9.4) | |
| PSAD, ng, mean (SD) | 0.20 (0.11) | |
| EBRT, n, (%) | 202 (13.9) | |
| ADT, n, (%) | 531 (36.4) |
SD = standard deviation; IQR = interquartile range; PSA = prostate-specific antigen; EBRT = external beam radiation therapy; ADT = androgen deprivation therapy; NA = not applicable; PSAD = PSA density; PPC = percent of positive cores.